IceCure Medical Publishes Mouse Study On ProSense That Boosts Immune Response Against Cancer

(RTTNews) - Provider of minimally-invasive cryoablation technology IceCure Medical Ltd. (ICCM) Wednesday announced the publication of a study titled 'Piezo1 facilitates optimal T cell activation during tumor challenge' in OncoImmunology journal.

The independent mouse model study, using ProSense demonstrated that cryoablation can activate the body's natural immune response by enhancing CD8+ T cells, an important arm of immune response.

The developer of ProSense said the data might produce anti-cancer benefits in humans beyond tumor destruction during cryoablation procedure.